Form 4: Denali CEO Ryan Watts Granted Equity Awards

Denali Therapeutics Inc. CEO Ryan J. Watts received grants of 78,960 Restricted Stock Units and options to purchase 236,880 shares of common stock.

Summary

• Ryan J. Watts, President and CEO of Denali Therapeutics Inc., was granted 78,960 Restricted Stock Units (RSUs) on January 3, 2026.
• Each RSU represents a contingent right to receive one share of common stock of the Issuer.
• The RSUs will vest 25% on January 3, 2027, and an additional 25% on each annual anniversary thereafter, contingent on continued service as a service provider of the Issuer.
• Watts also received options to purchase 236,880 shares of common stock with an exercise price of $16.27 per share.
• These stock options will vest 25% on January 3, 2027, and 1/48 of the shares subject to the option will vest each month thereafter, also contingent on continued service.
• The stock options have an expiration date of January 3, 2036.
• The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following these transactions, Watts directly beneficially owns 332,031 shares (including 184,915 unvested RSUs) and indirectly owns 2,152,604 shares through the Watts Family 2015 Trust.

Sentiment

Score: 7

Explanation: The filing indicates standard equity compensation for a CEO, which is generally positive for aligning interests but carries minor dilution implications. The transaction date of January 3, 2026, for a filing dated January 5, 2026, indicates a pre-scheduled grant, which is a common practice under Rule 10b5-1 plans.

Positives

• The equity grants align management's interests with long-term shareholder value through performance-based compensation.
• The multi-year vesting schedules for both RSUs and stock options incentivize the CEO to remain with the company and drive sustained performance.

Negatives

• The future issuance of shares upon RSU vesting and option exercise will result in some dilution for existing shareholders.

Risks

• The ultimate value realized from the RSUs and stock options is contingent on Denali Therapeutics Inc.'s stock performance and the CEO's continued employment with the company.

Future Outlook

The equity grants, with their multi-year vesting schedules, suggest an expectation of continued service from the CEO and a focus on long-term value creation for Denali Therapeutics Inc.

Industry Context

Equity compensation, including Restricted Stock Units and stock options, is a standard practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize key executives, aligning their performance with company growth and shareholder returns.

Related Party Transactions

• Indirect beneficial ownership of 2,152,604 shares through the Watts Family 2015 Trust, for which Ryan J. Watts serves as trustee.

Stakeholder Impact

• Shareholders: Potential for minor dilution from future share issuance upon vesting and exercise, but also benefit from incentivized management.
• Employees: No direct impact mentioned, but executive compensation practices can influence overall company culture and compensation strategies.

Next Steps

• Continued vesting of RSUs and stock options on January 3, 2027, and annually/monthly thereafter, subject to Ryan J. Watts's continued service.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for the CEO, which is a standard practice to align executive incentives with long-term shareholder value. It does not present new information that would fundamentally alter the investment thesis for Denali Therapeutics Inc., thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Denali Therapeutics, DNLI, Ryan Watts, SEC Form 4, Restricted Stock Units, Stock Options, Insider Transaction, Equity Compensation, CEO Compensation, Rule 10b5-1